Medindia

X

China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter 2009 Financial Results

Tuesday, November 4, 2008 General News J E 4
Advertisement
SHANGHAI, China, Nov. 3 China-Biotics,Inc. (Nasdaq: CHBT) ("China-Biotics," "the Company"), a leading Chinese firmspecializing in the research, development, manufacture, marketing anddistribution of probiotics dietary supplements, today announced it will host aconference call at 9:00 a.m. EST on Tuesday, November 11, 2008, to discuss theCompany's financial results for the second quarter ended September 30, 2008,of its fiscal 2009.

Hosting the call will be Jinan Song, Chairman and Chief Executive Officer,Raymond Li, Chief Financial Officer, and Henry Tai, Vice President ofCorporate Development.

To participate in the event by telephone, please dial 888-241-0558 five to10 minutes prior to the start time (to allow time for registration) andreference the conference ID 71784337. International callers should dial647-427-3417.

A digital replay of the call will be available on Tuesday, November 11 atapproximately 11:00 a.m. EST through Tuesday, November 18 at midnight EST. Tolisten to the replay, dial 800-677-6425 and enter the conference ID number71784337. International callers should dial 402-220-1449 and enter the sameconference ID number.

The conference call will also be webcast live over the Internet and can beaccessed by all interested parties at the company's Web site,http://www.chn-biotics.com .

To monitor the live webcast, please go to this web site at least 15minutes prior to the start of the call to register, download, and install anynecessary audio software. An audio replay of the event will be archived onChina-Biotics' Web site at http://www.chn-biotics.com/ for 90 days.

About China-Biotics, Inc.

China-Biotics, Inc. ("China-Biotics," "the Company"), a leadingmanufacturer of biotechnology products and supplements, engages in theresearch, development, marketing and distribution of probiotics dietarysupplements. Through its wholly owned subsidiary, Shanghai ShiningBiotechnology Co., Ltd., the Company has operations in Shanghai. Itsproprietary product portfolio contains live microbial nutritional supplementsunder the "Shining" brand. Currently, the products are sold OTC through largedistributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang.China-Biotics plans to launch 300 Shining brand retail outlets in major citiesin China. Currently, China-Biotics is strategically expanding its productioncapacity of probiotics to meet growing demand in the bulk additive market.For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Actof 1995: Any statements set forth above that are not historical facts areforward-looking statements that involve risks and uncertainties that couldcause actual results to differ materially from those in the forward-lookingstatements. Such factors include, but are not limited to, the Company'sability to market existing and new products, ability to access to capital forexpansion, and changes from anticipated levels of sales, future national orregional economic and competitive conditions, market acceptance of its retailstore concept, changes in relationships with customers, dependence on itsflagship product profits and other factors detailed from time to time in theCompany's filings with the United States Securities and Exchange Commissionand other regulatory authorities. The Company undertakes no obligation topublicly update or revise any forward-looking statements, whether as a resultof new information, future events or otherwise.For more information, please contact: CCG Investor Relations Crocker Coulson, President Tel: +1-646-213-1915 (New York) Email: crocker.coulson@ccgir.com Web: http://www.ccgirasia.com

SOURCE China-Biotics, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Tibotec Presents Interim Findings for TMC435, an I...
S
Sinovac Named to Deloitte Technology Fast 50 China